NCT04478071

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 448 (actual)
• Sponsor: The University of Texas Health Science Center, Houston · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).

Conditions

• Acute Respiratory Distress Syndrome
• Coronavirus Infection

Interventions

Type	Name	Description
DRUG	vadadustat	Participants will receive vadadustat once daily for 14 days.
DRUG	placebo	Participants will receive matching placebo once daily for 14 days.

Timeline

• Start date: 2020-08-22
• Primary completion: 2022-03-07
• Completion: 2022-03-25
• First posted: 2020-07-20
• Last updated: 2025-03-26
• Results posted: 2025-03-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study